SCHEMBL24387263

SCHEMBL24387263

C=C(CC(=O)OCc1ccc(OC)cc1)C(=O)OCCC(=O)OCC(Cl)(Cl)Cl

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.39
HTT P42858 2/20 0.38
LMNA P02545 1/20 0.38
RECQL P46063 1/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TP53 P04637 1/20 0.36
F2RL1 P55085 1/20 0.36
ATM Q13315 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24387802 0.91 ALDH1A1 (0.47) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL24387269 0.89 MAPT (0.36) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL24387360 0.89 ALDH1A1 (0.43) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL6430060 0.82 ALDH1A1 (0.55) ALDH1A1MAPK1L3MBTL1KMT2AGAA
SCHEMBL24397832 0.80 NPC1 (0.39) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL2575791 0.80 ALDH1A1 (0.55) ALDH1A1MAPK1L3MBTL1KMT2AGAA
SCHEMBL24387362 0.78 NPC1 (0.36) ALDH1A1MAPK1L3MBTL1HTTLMNA
SCHEMBL26958092 0.78 ALDH1A1 (0.50) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL4896275 0.78 ALDH1A1 (0.50) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL4893580 0.78 ALDH1A1 (0.50) ALDH1A1MAPK1L3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381132-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2023-11-30 US disclosed
US-20230381132-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2023-11-30 US disclosed
EP-4237402-A1 NOVEL COMPOUNDS Sitryx Therapeutics Limited (GB) 2023-09-06 EP disclosed
WO-2022090714-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2022-05-05 WO disclosed
WO-2022090714-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230381132-A1 NOVEL COMPOUNDS CNKSR1, RORC, RCOR3 ALDH1A1 311/4885MAPK1 756/4885L3MBTL1 3755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.